The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia.

Trial Profile

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Donepezil (Primary)
  • Indications Dementia; Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 08 Mar 2012 Actual patient number of the extension trial (NCT01327859) is 357.
    • 08 Mar 2012 Actual patient number of the extension trial (NCT01327859) is 357.
    • 08 Mar 2012 Planned end date of the extension trial (NCT01327859) is Jul 2006.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top